Some ongoing studies (Table 2) with ICIs treatments for mCRC are currently investigating PD-1/PD-L1 expression, T cell proportions, and gene expression on blood samples or serial tumor biopsies as a dynamic biomarker (Table 2). Here, PDCD1 is linked to neoplasm.